Items Tagged ‘lenvatinib’

May 24th, 2016

Lenvima® Approved for Kidney Cancer

By

The United States Food and Drug Administration (FDA) has approved Lenvima® (lenvatinib) for the treatment of kidney cancer. The approval is for patients with advanced renal cell carcinoma who have received at least one prior therapy with an anti-angiogenic agent, and is to be used in combination with the standard agent Afinitor® (everolimus). Each year […]

View full entry

Tags: afinitor, everolimus, fda, General Renal Cancer, kidney cancer, lenvatinib, Lenvima, News, rcc, Renal Cancer, RTK


May 28th, 2015

Lenvima®

By

Class: Biological Therapy Generic Name: Lenvatinib Trade Name: Lenvima® For which conditions is this drug approved? Lenvima is approved to treat people with a type of thyroid cancer called differentiated thyroid cancer (DTC) when the disease can no longer be treated with radioactive iodine and is progressing. It is also indicated for patients with advanced renal […]

View full entry

Tags: Biological Therapy, differentiated thyroid cancer, Drug Dictionary, L, lenvatinib, Lenvima, Thyroid Cancer


May 28th, 2015

Lenvatinib

By

Class: Biological Therapy Generic Name: Lenvatinib Trade Name: Lenvima® For which conditions is this drug approved? Lenvima is approved to treat people with a type of thyroid cancer called differentiated thyroid cancer (DTC) when the disease can no longer be treated with radioactive iodine and is progressing. It is also indicated for patients with advanced renal […]

View full entry

Tags: Biological Therapy, differentiated thyroid cancer, Drug Dictionary, L, lenvatinib, Lenvima, Thyroid Cancer


March 3rd, 2015

Lenvatinib; First Promising Treatment for Refractory Thyroid Cancer Patients in Years

By

In a pivotal Phase III study published in the New England Journal of Medicine, the oral anti-angiogenic therapy lenvatinib appears to be a very promising new treatment for patients with advanced radioiodine-refractory thyroid cancer. According to the National Cancer Institute, 60,000 people will be diagnosed with thyroid cancer in 2015 and almost 2,000 will die […]

View full entry

Tags: advanced radioiodine-refractory thyroid cancer, lenvatinib, New England Journal of Medicine, phase III, thyroid gland, tyrosine kinase inhibitors